MUC1 and neoplasm: Further support of the tumor cell- and MUC1 SP-specificity of the antibodies, was provided by absence of binding of SPmAb-2.1, SPmAb-6 mAbs and R23IgG antibodies to human white blood cells, in particular, to CD3+ T-cells, CD20+ B-cells and CD14+ myeloid cells, as well as to naïve normal human mammary epithelial cells (HMEC) (Table 2).